Try our Advanced Search for more refined results
Life Sciences - June, 2017
359 articles
- Product Liability Cases To Watch: Midyear Report
- Investor Says He Lost $4.8M As Shkreli Fund Failed
- Walgreen, Ocusoft Settle Eye Scrub Row
- Novartis Escapes End Payors' Gleevec Antitrust Suit
- Drug, Device Cos. Paid $8.2B To Doctors, Hospitals In 2016
- With No Bass In Drug Patent Appeal, USPTO Intervenes
- Canadian Justices Balk At 'Promise Doctrine' In Drug IP Row
- Taxation With Representation: Kirkland, WilmerHale, Latham
- NY Judge Won't Reconsider Tossing Of Pfizer's $8.3M Suit
- Opioid Users Join Fight Against Endo, Purdue, Teva
- DC Circ. Clears DEA To Block Opioid Supplier's Sales
- Health Hires: DR Welch, Greenspoon Grow Cannabis Teams
- What We're Watching In Ill.: Midyear Roundup
- SEC Asks 9th Circ. To Uphold Ex-NFLer's Negligence Verdict
- 3 Key Areas Legal Operations Teams Should Focus On
- Leegin's 10-Year Checkup: An Economist's Perspective
- Protecting And Enforcing Judgment Creditor Interests In IP
- What The Experts Said About High Court Rulings This Term
- Chamber Asks 7th Circ. Not To Revive Atty's Age Bias Suit
- Shkreli Investor Says She Felt 'Betrayed' By Bait And Switch
- J&J Says Calif. Talc Cancer Case Is Sunk By Shoddy Experts
- Allergan Settles Eye Doctor Kickback Suit For $13M
- Aveo Investors Want Class Cert. In Kidney Cancer Drug Spat
- Sandoz Wants Big Biosimilar Case Sent To District Court
- Bayer Launches $2M Suit Over Defective Sunscreen Ingredient
- St. Jude Says TC Heartland Beats Catheter Patent Suit
- Health Care Winners And Losers From The Better Care Act
- US Law Firms Face Discovery Of Foreign Clients' Records
- Leegin's 10-Year Checkup: Tips For Advising Clients On RPM
- Incentivizing Brand Pharma Cos. To Manufacture In The US
- The Future Of Law And The Demise Of The Midsize Firm
- Shkreli Atty Dubs Him 'Genius,' Denies Fraud As Trial Begins
- Pharmavite Gets OK On $1.9M Don-Doff, Wage, Break Deal
- Theranos Customers Defend Joint Venture, Battery Claims
- Amgen, Hospira Battle Over Experts Ahead Of Patent Trial
- Former Reed Smith Partner Joins Barton's Litigation Practice
- Pfizer, Direct Buyers Duel For Quick Wins In Celebrex Suit
- 6th Circ. Asked To Revive Spinal Patients' 'Disorganized' Suit
- Cravath Leads Spectranetics In €1.9B Sale To Philips
- The 10 Funniest Moments Of The Supreme Court Term
- The Most Talkative Justice Of The High Court Term
- The Cases That Got The Justices Talking
- Deals Rumor Mill: Sebia, KKR, Halliburton
- Sorrento Investor Suit Survives Dismissal Bid
- Leegin's 10-Year Checkup: No Big Changes In The Marketplace
- How Discovery Has Changed Under New Federal Rules
- Plaintiffs Bar Perspective: Beasley Allen's Andy Birchfield
- Innovating For Wise Juries: Pre-Voir Dire Questions
- Key Talc Expert Defends Cancer Link Ahead Of Calif. Trial
- Sonoma Pharma Beats Sanctions Bid Alleging Forged Letter
- CORRECTED: Pot Credit Union Can Again Seek KC Fed Account
- Fed. Circ. Vacates Invalidation Of Prenatal Testing Patent
- New FDA Chief Sheds Agency Hesitance On Drug Prices
- Shkreli Attorney Claims Bad Press Tainting Jury Pool
- Birth Control Patch Co. Shareholder Ends Stock-Drop Suit
- Gorsuch And Thomas Becoming Fast Friends At High Court
- FDA Warning Wire: Belladonna In Kids' Teething Products
- 5 High Court Concurrences That Read Like Dissents
- The Sharpest Dissents From This Supreme Court Term
- BMS, Sanofi Escape Plavix FCA Suit Under Escobar Standard
- Woman Drops Vitamin Shoppe Weight Loss Supplement Suit
- Deals Rumor Mill: Sprint, Stada, Sovcomflot
- Lincare Pays $20M To Resolve False Billing Probe
- Senate Bill May Force Rise In Suits For Opioid Funding
- Martin Shkreli Goes On Trial — What To Expect
- SEC Accuses 3 Of Illicit Ariad Trades
- Express Scripts Defends Privilege Log In Antitrust Suit
- Leegin's 10-Year Checkup: US Influence On RPM Overseas
- An Interview With Floyd Abrams
- J&J Battles Talc Cancer Expert Before First Calif. Trial
- Paul Hastings To Pay $46.5M In Deal To End ExamWorks Suit
- The Supreme Court Term By The Numbers
- The Firms That Won Big At The Supreme Court
- IP Cases Led The Pack In High Court Amicus Briefs
- Excess Insurer Says Akorn Suit Doesn't Need To Move To Ga.
- 4 Cos. Bolster IPO Pipeline With Filings Totaling $296M
- Bucking Tradition: NewLaw And The Coming Millennials
- Justices Won't Hear Sanctioned Atty's Fish Oil Class Action
- Docs Win Class Cert. In Botox Price-Inflation Action
- Pharmacist Gets 9 Years In Deadly Meningitis Outbreak
- CryoLife Claims Fraud In Battle Over $10M Merger Escrow
- Alaska Granted Intervention In DNA Testing Privacy Dispute
- Roche Defends Suit Over Alleged $89M Test Strip Scheme
- Leegin's 10-Year Checkup: State RPM Rules Vs. Federal Rule
- State AGs Responding To Trump Policies: 3 Areas To Watch
- Patent Exhaustion Ruling Will Affect Many Industries
- No Personal Jurisdiction Pass For Federal Plaintiffs
- Plaintiffs Bar Perspective: Susman Godfrey's Matthew Berry
- High Court Wants SG's Take On Vitamin C Price-Fix Dispute
- Gray Matters: We Feel, We Decide
- Fla. Gov. OKs Bill To Implement Med. Marijuana Expansion
- AbbVie Fights Hedge Funds' Bid To Return To State Court
- Top Product Liability Cases Of 2017: Midyear Report
- 8 Companies Perk Up IPO Pipeline With Deals Surpassing $1B
- Ex-BigLaw Atty Taps Proskauer For Post-Verdict Defense
- Clovis Reaches $142M Deal To Resolve Stock Drop Suit
- Pfizer Biosimilar Delayed By FDA Warning Letter
- House Debates Whether Atty 'Bad Drug' Ads Harm Patients
- Taxation With Representation: Sullivan, Vinson, Mayer
- Fed. Circ. Affirms USPTO's No-Matter-What Attys' Fees Rule
- Feds Seek 35 Years For Pharmacist In Meningitis Outbreak
- Leegin's 10-Year Checkup: RPM Rule Breeds Inconsistency
- TC Heartland Considerations For Hatch-Waxman Cases
- Farmers Awarded $218M In 1st Syngenta GMO Corn Trial
- Protect Innovation By Making FDA Compliance Admissible
- Feds, Shkreli Trade Claims Of Dubious Witness Tricks
- Inside Trader Must Shell Out $1.6M For Role In Sanofi Fraud
- AstraZeneca Affiliate Hit With $275M Merger Payment Suit
- Judge Denies Acquittal Bid In Meningitis Outbreak Case
- Pfizer Wins Interlocutory Review In Vfend Whistleblower Suit
- Patent Experts Broaden Merchant & Gould's NYC Office
- 2 Bellwethers Selected Against Lilly In Testosterone MDL
- Ind. Pharmacy Heads Charged With Selling Misdosed Drugs
- Hogan Lovells Adds Another Ex-Weil M&A Pro In Silicon Valley
- Purchasers Seek Cert. In Alere Blood Monitor Suit
- Mintz Levin Nabs Sedgwick Product Liability Litigators
- Justice Kennedy's Moderating Influence On The High Court
- Duty To Defend Doesn't Cover Counterclaims: Mass. Court
- The Shrinking Doctrine Of Specific Personal Jurisdiction
- Bard Investors Sue To Stop $24B Becton Dickinson Merger
- Justice Sotomayor On The Power Of Dissent
- Unilife, Competitor Spar Over Ch. 11 Sale Doc Access
- Forest Denied Drug Wholesalers' Profit Docs In Namenda Suit
- Altor Bioscience Suit Claims Insiders Lowballed Merger
- Impax Wants Goodwin Procter Barred In Teva Contract Fight
- Jones Day Expands IP Practice With 2 New Partners
- Inotek Investor Wants Look At Drug Test Statement Records
- A Bipartisan Call For STRONGER Patents
- Fed. Circ. Backs Gilead's Hep C Patent Win Against Idenix
- 2 Biotech Cos. Tap Follow-On Market For Nearly $500M
- Nobel Winner Attacks Sandoz Biosimilar Subpoena
- Innovating For Wise Juries: Juror-Posed Questions
- GSK Wins $235M Verdict Against Teva In Coreg Patent Fight
- News Outlet Presses Judge For Meningitis Juror Names
- FDA Says Drug Approval Scheme May Stymie Generics
- Convicted Pharmacist, Feds Fight Over Sentencing Range
- ITT Opens $1B Asbestos Coverage Trial Against 25 Insurers
- Medtronic Beats 'Free Services' Kickback FCA Suit, For Now
- Surgical Co. Investors Nab $7M Settlement In Stock-Drop Suit
- Burns & Levinson Boosts IP Bench With Technology Expert
- FDA Warning Wire: Zimmer Mea Culpa, Secret Steroids
- Salix Class Attys Seek $44.6M In Fees For $210M Settlement
- Actavis At 4: Pay-For-Delay Lawsuits Receding
- Merck Gets Out Of Patent Suit Over QR Codes
- Ionis Subsidiary Akcea Launches $125M IPO, Led By Cooley
- How 21st Century Cures Act Affects Combination Products
- Patheon Shareholders Sue To Stop $7.2B Thermo Fisher Deal
- Kirkland Steers Pamplona Capital In $5B Parexel Buyout
- Tough Times For Forum Shoppers
- FCA Lessons From A Year Of Escobar
- High Court Plavix Ruling To Shrink, Scatter Mass Torts
- Justice Sotomayor On Working A Room And The Post-Scalia Void
- Calistoga Tells Del. Justices It Earned $50M Drug Bonus
- Ex-ArthroCare CEO Invokes Honeycutt In Fraud Dismissal Bid
- Valeant Tries To Zap Claims In 4 Securities Fraud Suits
- Meal Kit Startup Blue Apron Leads Seven IPO Launches
- Ex-DOJ Consumer Protection Director Joins Venable
- Ex-Valeant CEO Blasts Drugmaker's Arbitration Bid
- Vinson & Elkins Welcomes Back Litigation Partner In Houston
- Ex-Sanofi Worker Fired For Reporting Misconduct, Suit Says
- Kimberly-Clark Can't Redo $454M Fraud Trial, Court Told
- J&J Talc Trial Derailed By High Court's Plavix Ruling
- Bard Settles 75 More Suits In Pelvic Mesh MDL
- The Evolution Of Opioid Suits And Insurance Coverage
- Ex-Insys Exec Cops To Opioid Fraud Scheme
- PerkinElmer Will Pay $1.3B For Germany's Euroimmun
- Pa. Judge Urged To Ax Defamation Suit Against Amerisource
- Pharma Cos. Tell Fed. Circ. To Reverse Durezol Decision
- 10 Problems To Avoid In Social Media Influencer Marketing
- High Court Says Plavix Suits Can't Stay In California
- FDA Will Investigate Pharma Promo Caveats, 'Overwarnings'
- 9th Circ. Won't Rethink New Falsity Standard Ruling
- Suture Co. Looks To Take Nixed Antitrust Suit To High Court
- Teva's Russian Subsidiary Pleads Guilty To FCPA Charge
- Fed. Circ. Nixes 3 Cleveland Clinic Test Patents Under Mayo
- Shkreli Wants Millions In Bail Back For Bills
- Humana Drops Pay-For-Delay Claims Against Boehringer
- Bristol-Myers Says Docs Knew Of Plavix Bleeding Risks
- Forest Says Namenda Buyers Can't Use Its Own Consultant
- The Latest On Escobar's FCA Impact
- Jurors With Strange Verdict In Meningitis Case To Be ID'ed
- One Year Later, Escobar Is Roiling FCA Landscape
- Hogan Lovells Expands To Boston, Combines With Collora
- SEC Says Maker Of Cannabis-Based Products Puffed Itself Up
- Gov't Statements Show Expansive View Of Escobar Liability
- Attys Dish On Escobar's FCA Impact One Year Later
- Ex-InterMune Exec, Friend Must Pay $746K For Insider Trading
- What DOJ Investigation Means For Generic Drug Plaintiffs
- How Science Days Are Changing Talc Litigation
- Actavis At 4: Where Pay-For-Delay Litigation Stands
- $15M Depakote Verdict A Bargaining Chip For Either Side
- FCA Decision Tracker: Continued Interpretations Of Escobar
- Tips For Complying With ABA's New Encryption Guidance
- J&J Appeals $48M Award Over Man's Severe Motrin Reaction
- State AGs Open Probe Into Opioid Drugmakers
- CytRx Floats Settlement Of Cross-Country Securities Suits
- Restless Legs Drugs Need Black Box Warnings, FDA Hears
- Ex-Pa. Doctor Sentenced To 25 Years For Running A Pill Mill
- Lilly Says Atty Fees Uncalled For After $20M Patent Loss
- Defective Bayer Warnings Led To Leg Amputation, Suit Says
- High Court's Superficial Analysis In Biosimilars Ruling
- HFF Helps Snag $75M Loan For San Francisco Tower
- Amazon Says Consumer Agreed To Its Terms In Diet Drug Row
- Derma Companies Ordered To Close Shop In FDA Row
- Pharmacist Says Feds' Misconduct Taints Meningitis Case
- 1st Circ. Clarifies Scienter Requirements
- Fed. Circ. Ruling Clears Judge To OK Mylan's Lialda Generic
- What's New About Germany's Merger Control Regime
- Rosen Firm Ends Bid To Lead NY Pharma Stock-Drop Class
- Justice Ginsburg On Oral Argument And 'Imperious' Attorneys
- Chancery Sends Innoviva Board Fight With Sarissa To Trial
- Ex-ArthroCare CFO Pleads Guilty After First Sentence Nixed
- Ranbaxy Pay-For-Delay Trial Kicks Off In Pa. Court
- Warner Chilcott Wins Transfer Of Ex-Sales Reps' Suit To NJ
- Drug Patents Fare Better At PTAB Than Others, Report Says
- Generics Makers Prevail In Menopause Drug Patent Trial
- Latham & Watkins Adds 2 Trial Pros From Kirkland & Ellis
- Cancer Drug Co. Athenex Raises $66M After IPO Prices Low
- Tenn. DAs, Addicted Baby's Guardian Sue Opioid Makers
- Rx Black Marketeer Must Repay $30M To NY Medicaid
- Firms Fight For Lead Role In Lion Biotech Investor Case
- Merck Wins PTAB Review Of Pfizer Pneumonia Vax Patent
- High Court Interprets The Biosimilars Statute — What Now?
- Theranos, Walgreens Get Blood Test Suit Largely Axed
- Texas Co. Sells Possibly Dangerous Supplement, Suit Says
- Ex-Exec, SEC Settle Suit Over Pump-And-Dump Reporting
- Alembic Pharma Gets Win In Generic Gilenya Patent Case
- Innovating For Wise Juries: Preliminary Instructions
- PTAB To Review Cialis Patent In Mylan Challenge
- FDA Warning Wire: Bad Drug Info, Lax Contact Lens Records
- McKesson, CVS Look To Toss, Pause Cherokee Opioid Suit
- Painkiller Patents Too Vague To Stand, Fed. Circ. Says
- Microsoft Ruling Backs Cymbalta Suit, Lilly Tells 9th Circ.
- Ex-MLB Player Fights Insider Trading Verdict
- Witness In $25M Med Device Trial Gets 15 Months For Lying
- Due Diligence From The Lateral Partner's Perspective
- Artery Imaging Device Co. Hit With Suit Over $65M IPO
- Patient In First Xarelto Bellwether Wants New Trial
- FDA Lines Up Forum On Abuse-Deterrent Opioids
- FDA Rejects Coherus Application For Neulasta Biosimilar
- Ga. Pharmacy Pays $2M To Resolve False Claims Act Probe
- Ex-Pot Co. Owner Seeks To Shift SEC Fraud Claims Onto Atty
- South Africa Probes Roche, Pfizer, Aspen Over Drug Pricing
- An Interview With Ex-USPTO Director Todd Dickinson: Part 2
- Lateral Partner Due Diligence: Where Should A Firm Begin?
- Justice Ginsburg On Diversity And Persuading Her Colleagues
- Talc Is Clearly Toxic, Expert Says In J&J Cancer Trial
- 6 Key Takeaways From High Court's Big Biosimilar Ruling
- Deals Rumor Mill: Toshiba, Bayer, Lotte
- Feds Seek $132.8M From Convicted Meningitis Fraudster
- Detroit Must Refund Income Tax To Passive Holding Company
- Bayer, Janssen Win 2nd Xarelto Bellwether Trial
- Lab Supplier's $6.4B Sale Has Investors In Dark, Suit Says
- Pfizer Combo Drug Gets New Exclusivity After Ferring Win
- An Interview With Ex-USPTO Director Todd Dickinson: Part 1
- Mistrial Declared In First Androgel Bellwether
- High Court Boosts Biosimilars By Allowing Early Notice
- 6th Circ. Affirms Ex-Atty's Lengthy Sentence In 2nd Appeal
- J&J Targeted Minorities With Deadly Talc, Jury Told
- GE Owes $131M Damages For Anesthesia Monopoly, Cos. Say
- Contention Gives Way To Compromise In Fla. Special Session
- Coherus Assails Amgen's Neulasta Biosimilar Suit
- Product Liability Regulation & Legislation: Midyear Report
- Bayer, Janssen Say Blood Thinner Warning Claim Preempted
- Philly Jury Clears J&J In Latest Pelvic Mesh Case
- Walgreens, McKesson Look To Block Cherokee Opioid Suit
- Native American Cases To Watch In The 2nd Half Of 2017
- EU Approves J&J's $30B Actelion Buy, With Conditions
- TC Heartland & Hatch-Waxman: The Sky's Not Falling
- Abbott Labs Hit With $15M Verdict In Depakote Trial
- Keys To Successful Swear-Behind Attempts Before PTAB
- FDA Asks Endo To Remove Opana ER, Citing Opioid Crisis
- 6 Highlights From Busy Health Policy Day On Capitol Hill
- Royalty Biz Seeks Toss Of Hedge Fund's Bid For Board Seats
- Northwestern Doc Says AbbVie's Androgel Has Heart Risks
- FTC Fights Watson's Bid To Block Lidoderm Antitrust Suit
- EU High Court Nixes German Co.'s Glucose Health Claims
- Essure Patients Say Suit Against Bayer Belongs In State Court
- Kyle Bass Gets Diprivan Patent Claims Nixed In PTAB Review
- 'Phantom Pain' Device Maker Misled Investors, Suit Says
- MoFo Nabs Wilson Sonsini Life Sciences Atty In SF
- Valeant Sells Aussie Pharma Biz To PE Shops For $930M
- NJ Drugmaker Accuses Ex-Partner Co. Of Defamation
- Foley & Lardner Adds Ex-Ropes & Gray Atty To NY Office
- Fla. Legislature Reaches Deal To Address Medical Marijuana
- Robbins Geller To Lead Investor Suit Over Sequenom Deal
- Depakote Birth Defect Trial Goes To Jury With Plea For $40M
- J&J Reaches Deal In 'Natural' Sunscreen Suit
- Stryker Unit Says Biomet Trade Secret Suit Should Proceed
- Mylan, Others Rigged Generic Drug Prices, Suits Say
- Sessions Stops 3rd-Party Donation Settlements
- Insurer Tells 3rd Circ. That Carriers Liable In $9M Drug Theft
- Deals Rumor Mill: Allianz, Lotte Group, Alitalia
- La. Not Immune From Flonase Class Settlement, Says GSK
- Stockholder Demands Look At Ambry Genetics' Books
- Device Maker, UPenn Sued For Heart Surgery Infection
- Roche Faces Stock Drop Suit Over Cancer Drug Results
- Plaintiffs Bar Perspective: Motley Rice's Donald Migliori
- Innovating For Wise Juries: Setting Trial Time Limits
- Drug Co. Sellers Ask Nix Of Fraud Claims In $2B Teva Suit
- Carlyle, GTCR Ink $21.75-Per-Share Buyout Of AMRI
- Bayer Asks For Block Of CAP IM Anti-Tick Dog Treatment
- Big Business Lobby Tries To Hobble Litigation Finance, Again
- Novartis Wins $2M Over Ex-Employee's Tossed Bias Suit
- McCarter & English Adds 2 Product Liability Litigators
- Halt Medical Cleared For Ch. 11 Asset Sale To DIP Lender
- FDA Warning Wire: Big Generic-Drug Cos., OTC Biz Scolded
- Ex-FDA Head Says AbbVie Promoted Off-Label Androgel Use
- 3rd Circ. Could Upset Class Pacts In Flonase Antitrust Row
- Ex-Insys Manager Will Plead Guilty To Insurance Fraud
- Olympus Settles Pa. Suit Over FDA-Flagged Surgical Tool
- Amgen Patents Don't Advance Drug Science, Fed. Circ. Told
- Deals Rumor Mill: Valeant, Snap, WuXi Biologics
- FTC, AbbVie Seek Quick Wins In Androgel Antitrust Suit
- Sloan Kettering Secures Sanctions In Drug IP Case
- Lessons From Risk Minimization FCA Cases Post-Escobar
- After The BNSF Decision, There's No Place Like 'At Home'
- AbbVie Confronts 1st Bellwether In Androgel MDL
- Colgate Seeks Stay Of 2 Cases Until FDA Defines 'Natural'
- Investor's Smear-And-Short Judgment, Case Tossed In Del.
- Cancer-Focused Biotech Co. Athenex Launches $72M IPO
- Express Scripts, CVS Face ERISA Suit Over EpiPen Costs
- Corp. Attys Back Drug Co. In FTC Privilege Fight At DC Circ.
- FDA, Amgen Shelve Sensipar Exclusivity Case
- Express Scripts Must Face Antitrust Suit, NY Pharmacy Says
- Akorn Says Excess Insurer Sued Too Soon Over $20M Verdict
- Enzo, Yale Push To Revive $61M Patent Award Over DNA Tech
- Lincare FCA Settlement Awaits DOJ Approval
- Vapor Smoke And Mirrors: The Future Of E-Cigarettes
- Congressional Forecast: June
- Diabetes Test Supplier Wants Abbott's Protected Emails
- 6 Suits Say Mylan, Others Rigged Generic Drug Prices
- Teva To Face Cancer Liability Claims In 9th Circ. Reversal
- Meal Kit Startup Blue Apron Leads 7 New IPO Filings
- Drug Return Co. Wants Acquittal, New Trial In $116M Fraud
- Health Hires: Epstein, Greenberg, McDermott, Polsinelli
- 3rd Circ. Upholds Pfizer Win In Zoloft Birth Defect MDL
- Pharma Co., Ex-CEO Fight Over Disqualifying Counsel
- Stanford, ThermoLife Seek To Slash Fee Award In IP Suit
- German Co. Seeks Attys' Fees In $20M Cialis IP Trial
- Patterson Thuente Nabs Patent Prosecutor For Sciences Team
- Feds Say Shkreli's Past Fund Failures Relevant To Trial
- Judge OKs DS Heathcare's $2.1M Stock Drop Settlement
- SEC's Win In NFLer Stock Scam Suit Improper, Atty Says
- CryoLife Trying To Swipe $10M Merger Escrow, Investors Say
- Dr. Spared Fine Over Accountant's Stock Sale Tax Gaffes
- NJ Stryker Hip Implant Suits Consolidated In State Court
- Deals Rumor Mill: Stitch Fix, SoftBank, Tesaro
- JPML Won't Combine Suits Over Memory Booster Prevagen
- Actos Buyers Fight To Preserve Market-Exclusivity Suit
- No Basis For FTC Lidoderm Pay-For-Delay Suit, Watson Says
- J&J Seeks Pause In 'Natural' Baby Wash Suit
- Ohio Sues Cephalon, Purdue, Endo Over Opioid Crisis
- B. Braun's Generic Infringes 2 Painkiller Patents, Rival Says
- Bard Hit With Antitrust Suit Over Alleged Catheter Tying
- No Tax Relief For New Mexico's Marijuana Businesses
- Janssen Takes Another 'Patent Dance' Step In Remicade Case
- Levi & Korsinsky Will Lead Insys Shareholder Suit
- Talc Talk: 1 Of These Verdicts Is Not Like The Others